{"id":2332,"date":"2020-07-27T00:00:00","date_gmt":"2020-07-27T00:00:00","guid":{"rendered":"http:\/\/centogene.vl22350.dinaserver.com\/2332"},"modified":"2020-07-27T00:00:00","modified_gmt":"2020-07-27T00:00:00","slug":"centogene-and-molecular-health-announce-an-exclusive-collaboration-with-the-aim-to-transform-the-development-of-orphan-drugs","status":"publish","type":"post","link":"https:\/\/www.centogene.com\/pl\/centogene-and-molecular-health-announce-an-exclusive-collaboration-with-the-aim-to-transform-the-development-of-orphan-drugs\/","title":{"rendered":"CENTOGENE i Molecular Health og\u0142aszaj\u0105 ekskluzywn\u0105 wsp\u00f3\u0142prac\u0119 maj\u0105c\u0105 na celu transformacj\u0119 rozwoju lek\u00f3w sierocych"},"content":{"rendered":"<p>Cambridge, MA, USA &amp; Rostock\/Berlin, Germany, and Heidelberg, Germany, July 27, 2020 (Globe Newswire)<\/p>\n<ul>\n<li>The combination of real-life data sets in rare diseases with innovative big data\/artificial intelligence\/novel scientific computational knowledge will transform biomedical research, product development, and therapy.<\/li>\n<li>Real-life data and Innovative Bioinformatic Algorithms (RIBA project) will enable the creation of a powerful environment to accelerate, de-risk, and improve the development of new orphan drugs for many diseases and disease areas.<\/li>\n<li>RIBA develops and offers data-\/computing-driven solutions to guide the highest and most precise innovation for a new way of drug development in a modern biopharmaceutical environment.<\/li>\n<li>The collaboration will start with Epilepsy as the first indication<\/li>\n<\/ul>\n<p>Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, and Molecular Health, a leading company in the field of data and computing science for precision medicine, announced today that they will collaborate exclusively to initiate the Real-life data and Innovative Bioinformatic Algorithms (RIBA) project \u2013 starting with Epilepsy as the first indication. RIBA aims to foster a unique novel precision medicine environment to accelerate, de-risk, and improve the development of new orphan drugs based on the combination of large real-life data sets in rare disease with innovative big data, innovative artificial intelligence, as well as computational algorithms and expertise. Both companies are convinced that this strategy of merging real-life data with a global curated biomedical knowledge, as well as applying artificial intelligence and scientific computing will radically change and transform biomedical research, product development, and therapy. Additionally, it will offer data-\/computing-driven solutions to guide the highest and most precise innovation for the new way of drug development in a modern biopharmaceutical environment.<\/p>\n<p>Prof. Arndt Rolfs, CENTOGENE Chief Executive Officer, stated, \u201cWe are excited about this collaboration. Both companies have been analyzing the potential interaction for an extended period of time and are deeply convinced that now is the right time to start an exclusive cooperation focusing on rare genetic diseases. The complementary expertise and knowledge of both companies will allow us to reduce the time to develop a new orphan drug by combining of real-life data and innovative computational biomedical expertise. CentoMD\u00ae, one of the world\u2019s largest rare disease data repositories, allows us to take advantage of the high quality of the real-life data from a global cohort of more than 500,000 consented patients. The extraordinary expertise of Molecular Health will not only speed up the identification of new targets in rare disease, but also allow us to de-risk and accelerate the development of new orphan drugs.\u201d<\/p>\n<p>\u201cBy starting this exciting collaboration between our companies, we are initiating and building a unique novel model of personalized healthcare. The combination of both companies\u2019 data and expertise will ultimately transform modern drug development and therapy. It will allow for the development of better drugs with higher specificity and safety, lower attrition rates in clinical studies, and a faster time to market to help patients with severe diseases worldwide through novel therapies,\u201d said Dr. Friedrich von Bohlen, Molecular Health Chief Executive Officer. \u201cTogether with CENTOGENE, Molecular Health\u00b4s deep scientific, medical, and computational expertise will lay the fundament for personalized healthcare options in rare diseases to fulfill the promise of precision medicine.\u201d<\/p>\n<p>The companies have agreed to start with Epilepsy as the first indication. Financial details were not disclosed.<\/p>\n<h2 class=\"h3\">O firmie CENTOGENE<\/h2>\n<p>CENTOGENE zajmuje si\u0119 diagnostyk\u0105 i badaniami nad chorobami rzadkimi, przekszta\u0142caj\u0105c rzeczywiste dane kliniczne i genetyczne w praktyczne informacje dla pacjent\u00f3w, lekarzy i firm farmaceutycznych. Naszym celem jest racjonalizacja decyzji terapeutycznych i przyspieszenie rozwoju nowych lek\u00f3w sierocych, wykorzystuj\u0105c nasz\u0105 rozleg\u0142\u0105 wiedz\u0119 na temat chor\u00f3b rzadkich, w tym dane epidemiologiczne i kliniczne, a tak\u017ce innowacyjne biomarkery. CENTOGENE opracowa\u0142o globaln\u0105, autorsk\u0105 platform\u0119 chor\u00f3b rzadkich opart\u0105 na naszym repozytorium danych z rzeczywistego \u015bwiata, obejmuj\u0105cym oko\u0142o 3 miliardy wa\u017conych punkt\u00f3w danych od ponad 530 000 pacjent\u00f3w z ponad 120 kraj\u00f3w (stan na 31 marca 2020 r.).<\/p>\n<p>Platforma firmy obejmuje dane epidemiologiczne, fenotypowe i genetyczne, kt\u00f3re odzwierciedlaj\u0105 globaln\u0105 populacj\u0119, a tak\u017ce biobank pr\u00f3bek krwi tych pacjent\u00f3w. CENTOGENE uwa\u017ca, \u017ce jest to jedyna platforma, kt\u00f3ra kompleksowo analizuje dane wielopoziomowe w celu lepszego zrozumienia rzadkich chor\u00f3b dziedzicznych, co mo\u017ce pom\u00f3c w identyfikacji pacjent\u00f3w i usprawni\u0107 wprowadzanie lek\u00f3w sierocych na rynek przez naszych partner\u00f3w farmaceutycznych. Na dzie\u0144 31 marca 2020 r. firma wsp\u00f3\u0142pracowa\u0142a z 39 partnerami farmaceutycznymi, obejmuj\u0105cymi ponad 45 r\u00f3\u017cnych chor\u00f3b rzadkich.<\/p>\n<h2 class=\"h3\">About Molecular Health<\/h2>\n<p>Molecular Health is a data science-focused artificial intelligence computing company enabling and improving decision making in precision medicine for healthcare organizations. The company offerings are based on the capture, curation, integration, and analysis of large biomedical and drug data sets and combining them with novel artificial intelligence and machine learning (AI\/ML) technologies.<\/p>\n<p>For more than a decade, the company has been developing Dataome, a unique high-quality curated, interoperable system that combines clinico-molecular and drug data with proprietary analytical processes. Dataome \u2013 stand alone or in combination with customer data \u2013 enables the unlocking of actionable intelligence at the molecular level to a) improve diagnosis and therapy decisions by physicians and patients; b) enrich and support better drug discovery, drug development, trial optimization, drug differentiation and positioning for pharma and healthcare organizations; and c) more accurately predict the likelihood of success and likelihood of approval of drug candidates in clinical development for better trial prioritization and resource and investment allocation. For more information visit <a href=\"http:\/\/www.molecularhealth.com\" target=\"_blank\" title=\"Uzyskaj wi\u0119cej informacji\">the website.<\/a><\/p>\n<h5>Kontakt dla medi\u00f3w:<\/h5>\n<p>CENTOGENE<br \/> Melissa Hall<br \/> Komunikacja korporacyjna<br \/> <a href=\"mailto:press@centogene.com\" title=\"Napisz e-mail\">press@centogene.com<\/a><\/p>\n<p>Molecular Health GmbH<br \/> Thomas K\u00f6nig<br \/> Head of Communications &amp; PR<br \/> <a href=\"mailto:media@molecularhealth.com\" title=\"Napisz e-mail\">media@molecularhealth.com<\/a><\/p>\n<p>MC Services AG<br \/> Anne Hennecke\/Susanne Kutter<br \/> +49 211 529252 22 \/ +49 211 529252 27<br \/> <a href=\"mailto:centogene@mc-services.eu\" title=\"Napisz e-mail\">centogene@mc-services.eu<\/a><\/p>\n<p>Katja Arnold\/Eva Bauer<br \/> +49-89-210 228 0<br \/> <a href=\"mailto:Molecularhealth@mc-services.eu\" title=\"Napisz e-mail\">Molecularhealth@mc-services.eu<\/a><\/p>\n<p>Doradztwo FTI<br \/> Bridie Lawlor<br \/> +1.917.929.5684<br \/> <a href=\"mailto:bridie.lawlor@fticonsulting.com\" title=\"Napisz e-mail\">bridie.lawlor@fticonsulting.com<\/a><\/p>\n<h5>Wa\u017cna informacja i wy\u0142\u0105czenie odpowiedzialno\u015bci<strong> <\/strong><\/h5>\n<p>Niniejsza informacja prasowa zawiera stwierdzenia stanowi\u0105ce \u201cstwierdzenia dotycz\u0105ce przysz\u0142o\u015bci\u201d zgodnie z definicj\u0105 tego terminu zawart\u0105 w ameryka\u0144skiej ustawie o reformie przepis\u00f3w procesowych dotycz\u0105cych papier\u00f3w warto\u015bciowych z 1995 r. (Private Securities Litigation Reform Act of 1995), w tym stwierdzenia wyra\u017caj\u0105ce opinie, oczekiwania, przekonania, plany, cele, za\u0142o\u017cenia lub prognozy Sp\u00f3\u0142ki dotycz\u0105ce przysz\u0142ych zdarze\u0144 lub wynik\u00f3w, w przeciwie\u0144stwie do stwierdze\u0144 odzwierciedlaj\u0105cych fakty historyczne. Przyk\u0142adami s\u0105 om\u00f3wienia naszych strategii, plan\u00f3w finansowania, mo\u017cliwo\u015bci rozwoju i wzrostu rynku. W niekt\u00f3rych przypadkach takie stwierdzenia dotycz\u0105ce przysz\u0142o\u015bci mo\u017cna zidentyfikowa\u0107 po terminologii, takiej jak \u201cprzewidywa\u0107\u201d, \u201czamierza\u0107\u201d, \u201cwierzy\u0107\u201d, \u201cszacowa\u0107\u201d, \u201cplanowa\u0107\u201d, \u201cd\u0105\u017cy\u0107\u201d, \u201cprognozowa\u0107\u201d lub \u201coczekiwa\u0107\u201d, \u201cmo\u017ce\u201d, \u201cb\u0119dzie\u201d, \u201cby\u0142by\u201d, \u201cm\u00f3g\u0142by\u201d lub \u201cpowinien\u201d \u2013 formy przecz\u0105ce tych termin\u00f3w lub podobne. Stwierdzenia dotycz\u0105ce przysz\u0142o\u015bci oparte s\u0105 na aktualnych przekonaniach i za\u0142o\u017ceniach kierownictwa oraz na informacjach, do kt\u00f3rych Sp\u00f3\u0142ka ma obecnie dost\u0119p. Jednak\u017ce te stwierdzenia dotycz\u0105ce przysz\u0142o\u015bci nie stanowi\u0105 gwarancji naszych wynik\u00f3w i nie nale\u017cy na nich nadmiernie polega\u0107. O\u015bwiadczenia prognostyczne podlegaj\u0105 wielu czynnikom ryzyka, niepewno\u015bci i innym zmiennym okoliczno\u015bciom, takim jak niekorzystne warunki gospodarcze na \u015bwiecie oraz ci\u0105g\u0142a niestabilno\u015b\u0107 i zmienno\u015b\u0107 na \u015bwiatowych rynkach finansowych, wp\u0142yw pandemii COVID-19 na nasz\u0105 dzia\u0142alno\u015b\u0107 i wyniki operacyjne, mo\u017cliwe zmiany w obowi\u0105zuj\u0105cych i proponowanych przepisach, regulacjach i polityce rz\u0105dowej, presja wynikaj\u0105ca z rosn\u0105cej konkurencji i konsolidacji w naszej bran\u017cy, koszty i niepewno\u015b\u0107 zwi\u0105zana z zatwierdzeniem regulacyjnym, w tym przez Ameryka\u0144sk\u0105 Agencj\u0119 ds. \u017bywno\u015bci i Lek\u00f3w (FDA), nasze uzale\u017cnienie od podmiot\u00f3w zewn\u0119trznych i partner\u00f3w, w tym nasza zdolno\u015b\u0107 do zarz\u0105dzania wzrostem i nawi\u0105zywania nowych relacji z klientami, nasza zale\u017cno\u015b\u0107 od bran\u017cy chor\u00f3b rzadkich, nasza zdolno\u015b\u0107 do zarz\u0105dzania ekspansj\u0105 mi\u0119dzynarodow\u0105, nasza zale\u017cno\u015b\u0107 od kluczowego personelu, nasza zale\u017cno\u015b\u0107 od ochrony w\u0142asno\u015bci intelektualnej, wahania naszych wynik\u00f3w operacyjnych spowodowane wp\u0142ywem kurs\u00f3w walutowych lub innych czynnik\u00f3w. Takie ryzyka i niepewno\u015bci mog\u0105 spowodowa\u0107, \u017ce o\u015bwiadczenia b\u0119d\u0105 niedok\u0142adne, a czytelnik\u00f3w ostrzega si\u0119 przed nadmiernym poleganiem na takich o\u015bwiadczeniach. Wiele z tych ryzyk jest poza kontrol\u0105 Sp\u00f3\u0142ki i mo\u017ce spowodowa\u0107, \u017ce jej rzeczywiste wyniki b\u0119d\u0105 istotnie r\u00f3\u017cni\u0107 si\u0119 od tych, kt\u00f3rych si\u0119 spodziewa\u0142a. O\u015bwiadczenia prognostyczne zawarte w niniejszym komunikacie prasowym s\u0105 aktualne wy\u0142\u0105cznie na dzie\u0144 jego publikacji. Sp\u00f3\u0142ka nie zobowi\u0105zuje si\u0119, a w szczeg\u00f3lno\u015bci nie zobowi\u0105zuje si\u0119 do aktualizacji takich o\u015bwiadcze\u0144 ani do publicznego og\u0142aszania skutk\u00f3w jakichkolwiek zmian w tych o\u015bwiadczeniach w celu odzwierciedlenia przysz\u0142ych zdarze\u0144 lub wydarze\u0144, z wyj\u0105tkiem przypadk\u00f3w wymaganych przez prawo.<\/p>\n<p>Aby uzyska\u0107 wi\u0119cej informacji, zapoznaj si\u0119 z sekcj\u0105 \u201eCzynniki ryzyka\u201d w naszym Raporcie Rocznym za rok obrotowy zako\u0144czony 31 grudnia 2019 r. na formularzu 20-F z\u0142o\u017conym w Komisji Papier\u00f3w Warto\u015bciowych i Gie\u0142d (SEC) 23 kwietnia 2020 r. oraz w innych bie\u017c\u0105cych raportach i dokumentach z\u0142o\u017conych w Komisji Papier\u00f3w Warto\u015bciowych i Gie\u0142d (SEC). Dokumenty te mo\u017cna uzyska\u0107 na stronie EDGAR. <a href=\"http:\/\/www.sec.gov\" target=\"_blank\" title=\"Link do strony internetowej SEC\">na stronie internetowej SEC.<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Cambridge, MA, USA &amp; Rostock\/Berlin, Germany, and Heidelberg, Germany, July 27, 2020 (Globe Newswire) The combination of real-life data sets [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2332","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CENTOGENE and Molecular Health Announce an Exclusive Collaboration With the Aim to Transform the Development of Orphan Drugs | CENTOGENE<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.centogene.com\/pl\/centogene-and-molecular-health-announce-an-exclusive-collaboration-with-the-aim-to-transform-the-development-of-orphan-drugs\/\" \/>\n<meta property=\"og:locale\" content=\"pl_PL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CENTOGENE and Molecular Health Announce an Exclusive Collaboration With the Aim to Transform the Development of Orphan Drugs | CENTOGENE\" \/>\n<meta property=\"og:description\" content=\"Cambridge, MA, USA &amp; Rostock\/Berlin, Germany, and Heidelberg, Germany, July 27, 2020 (Globe Newswire) The combination of real-life data sets [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.centogene.com\/pl\/centogene-and-molecular-health-announce-an-exclusive-collaboration-with-the-aim-to-transform-the-development-of-orphan-drugs\/\" \/>\n<meta property=\"og:site_name\" content=\"CENTOGENE\" \/>\n<meta property=\"article:published_time\" content=\"2020-07-27T00:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"740\" \/>\n\t<meta property=\"og:image:height\" content=\"416\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"admincg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Napisane przez\" \/>\n\t<meta name=\"twitter:data1\" content=\"admincg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Szacowany czas czytania\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-and-molecular-health-announce-an-exclusive-collaboration-with-the-aim-to-transform-the-development-of-orphan-drugs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-and-molecular-health-announce-an-exclusive-collaboration-with-the-aim-to-transform-the-development-of-orphan-drugs\\\/\"},\"author\":{\"name\":\"admincg\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\"},\"headline\":\"CENTOGENE and Molecular Health Announce an Exclusive Collaboration With the Aim to Transform the Development of Orphan Drugs\",\"datePublished\":\"2020-07-27T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-and-molecular-health-announce-an-exclusive-collaboration-with-the-aim-to-transform-the-development-of-orphan-drugs\\\/\"},\"wordCount\":1417,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"pl-PL\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-and-molecular-health-announce-an-exclusive-collaboration-with-the-aim-to-transform-the-development-of-orphan-drugs\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-and-molecular-health-announce-an-exclusive-collaboration-with-the-aim-to-transform-the-development-of-orphan-drugs\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/centogene-and-molecular-health-announce-an-exclusive-collaboration-with-the-aim-to-transform-the-development-of-orphan-drugs\\\/\",\"name\":\"CENTOGENE and Molecular Health Announce an Exclusive Collaboration With the Aim to Transform the Development of Orphan Drugs | CENTOGENE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\"},\"datePublished\":\"2020-07-27T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-and-molecular-health-announce-an-exclusive-collaboration-with-the-aim-to-transform-the-development-of-orphan-drugs\\\/#breadcrumb\"},\"inLanguage\":\"pl-PL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-and-molecular-health-announce-an-exclusive-collaboration-with-the-aim-to-transform-the-development-of-orphan-drugs\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-and-molecular-health-announce-an-exclusive-collaboration-with-the-aim-to-transform-the-development-of-orphan-drugs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.centogene.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CENTOGENE and Molecular Health Announce an Exclusive Collaboration With the Aim to Transform the Development of Orphan Drugs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"name\":\"CENTOGENE\",\"description\":\"Guiding Precision Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.centogene.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pl-PL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\",\"name\":\"CENTOGENE\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pl-PL\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"contentUrl\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"width\":246,\"height\":246,\"caption\":\"CENTOGENE\"},\"image\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/centogene\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UClZxtN_laC1_ZtCdxkasdPQ\",\"https:\\\/\\\/www.instagram.com\\\/_centogene_\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\",\"name\":\"admincg\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/pl\\\/author\\\/admincg\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CENTOGENE and Molecular Health Announce an Exclusive Collaboration With the Aim to Transform the Development of Orphan Drugs | CENTOGENE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.centogene.com\/pl\/centogene-and-molecular-health-announce-an-exclusive-collaboration-with-the-aim-to-transform-the-development-of-orphan-drugs\/","og_locale":"pl_PL","og_type":"article","og_title":"CENTOGENE and Molecular Health Announce an Exclusive Collaboration With the Aim to Transform the Development of Orphan Drugs | CENTOGENE","og_description":"Cambridge, MA, USA &amp; Rostock\/Berlin, Germany, and Heidelberg, Germany, July 27, 2020 (Globe Newswire) The combination of real-life data sets [&hellip;]","og_url":"https:\/\/www.centogene.com\/pl\/centogene-and-molecular-health-announce-an-exclusive-collaboration-with-the-aim-to-transform-the-development-of-orphan-drugs\/","og_site_name":"CENTOGENE","article_published_time":"2020-07-27T00:00:00+00:00","og_image":[{"width":740,"height":416,"url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp","type":"image\/webp"}],"author":"admincg","twitter_card":"summary_large_image","twitter_misc":{"Napisane przez":"admincg","Szacowany czas czytania":"7 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.centogene.com\/centogene-and-molecular-health-announce-an-exclusive-collaboration-with-the-aim-to-transform-the-development-of-orphan-drugs\/#article","isPartOf":{"@id":"https:\/\/www.centogene.com\/centogene-and-molecular-health-announce-an-exclusive-collaboration-with-the-aim-to-transform-the-development-of-orphan-drugs\/"},"author":{"name":"admincg","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b"},"headline":"CENTOGENE and Molecular Health Announce an Exclusive Collaboration With the Aim to Transform the Development of Orphan Drugs","datePublished":"2020-07-27T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.centogene.com\/centogene-and-molecular-health-announce-an-exclusive-collaboration-with-the-aim-to-transform-the-development-of-orphan-drugs\/"},"wordCount":1417,"commentCount":0,"publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"pl-PL","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.centogene.com\/centogene-and-molecular-health-announce-an-exclusive-collaboration-with-the-aim-to-transform-the-development-of-orphan-drugs\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.centogene.com\/centogene-and-molecular-health-announce-an-exclusive-collaboration-with-the-aim-to-transform-the-development-of-orphan-drugs\/","url":"https:\/\/www.centogene.com\/centogene-and-molecular-health-announce-an-exclusive-collaboration-with-the-aim-to-transform-the-development-of-orphan-drugs\/","name":"CENTOGENE and Molecular Health Announce an Exclusive Collaboration With the Aim to Transform the Development of Orphan Drugs | CENTOGENE","isPartOf":{"@id":"https:\/\/www.centogene.com\/#website"},"datePublished":"2020-07-27T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.centogene.com\/centogene-and-molecular-health-announce-an-exclusive-collaboration-with-the-aim-to-transform-the-development-of-orphan-drugs\/#breadcrumb"},"inLanguage":"pl-PL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.centogene.com\/centogene-and-molecular-health-announce-an-exclusive-collaboration-with-the-aim-to-transform-the-development-of-orphan-drugs\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.centogene.com\/centogene-and-molecular-health-announce-an-exclusive-collaboration-with-the-aim-to-transform-the-development-of-orphan-drugs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.centogene.com\/"},{"@type":"ListItem","position":2,"name":"CENTOGENE and Molecular Health Announce an Exclusive Collaboration With the Aim to Transform the Development of Orphan Drugs"}]},{"@type":"WebSite","@id":"https:\/\/www.centogene.com\/#website","url":"https:\/\/www.centogene.com\/","name":"CENTOGENE","description":"Kierowanie medycyn\u0105 precyzyjn\u0105","publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.centogene.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pl-PL"},{"@type":"Organization","@id":"https:\/\/www.centogene.com\/#organization","name":"CENTOGENE","url":"https:\/\/www.centogene.com\/","logo":{"@type":"ImageObject","inLanguage":"pl-PL","@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","contentUrl":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","width":246,"height":246,"caption":"CENTOGENE"},"image":{"@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/centogene","https:\/\/www.youtube.com\/channel\/UClZxtN_laC1_ZtCdxkasdPQ","https:\/\/www.instagram.com\/_centogene_\/"]},{"@type":"Person","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b","name":"admincg","url":"https:\/\/www.centogene.com\/pl\/author\/admincg\/"}]}},"_links":{"self":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts\/2332","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/comments?post=2332"}],"version-history":[{"count":0,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/posts\/2332\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/media?parent=2332"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/categories?post=2332"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.centogene.com\/pl\/wp-json\/wp\/v2\/tags?post=2332"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}